BioSyent Inc. RX.V Stock
BioSyent Inc. Price Chart
BioSyent Inc. RX.V Financial and Trading Overview
BioSyent Inc. stock price | 8.65 CAD |
Previous Close | 7.2 CAD |
Open | 7.2 CAD |
Bid | 7.23 CAD x 0 |
Ask | 7.25 CAD x 0 |
Day's Range | 7.23 - 7.25 CAD |
52 Week Range | 6.24 - 8.3 CAD |
Volume | 2.01K CAD |
Avg. Volume | 5.24K CAD |
Market Cap | 87.39M CAD |
Beta (5Y Monthly) | 0.791245 |
PE Ratio (TTM) | 17.634146 |
EPS (TTM) | 0.53 CAD |
Forward Dividend & Yield | 0.16 (2.22%) |
Ex-Dividend Date | June 1, 2023 |
1y Target Est | 9 CAD |
RX.V Valuation Measures
Enterprise Value | 62.16M CAD |
Trailing P/E | 17.634146 |
Forward P/E | 15.382978 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.1929529 |
Price/Book (mrq) | 2.616721 |
Enterprise Value/Revenue | 2.271 |
Enterprise Value/EBITDA | 9.545 |
Trading Information
BioSyent Inc. Stock Price History
Beta (5Y Monthly) | 0.791245 |
52-Week Change | -5.61% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8.3 CAD |
52 Week Low | 6.24 CAD |
50-Day Moving Average | 7.55 CAD |
200-Day Moving Average | 7.42 CAD |
RX.V Share Statistics
Avg. Volume (3 month) | 5.24K CAD |
Avg. Daily Volume (10-Days) | 12.79K CAD |
Shares Outstanding | 12.09M |
Float | 9.43M |
Short Ratio | 0.5 |
% Held by Insiders | 40.77% |
% Held by Institutions | 1.31% |
Shares Short | 1.51K |
Short % of Float | N/A |
Short % of Shares Outstanding | 0.010% |
Dividends & Splits
Trailing Annual Dividend Rate | 0.08 |
Trailing Annual Dividend Yield | 1.11% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.1975 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 18.43% |
Operating Margin (ttm) | 22.87% |
Gross Margin | 82.57% |
EBITDA Margin | 23.79% |
Management Effectiveness
Return on Assets (ttm) | 10.21% |
Return on Equity (ttm) | 15.41% |
Income Statement
Revenue (ttm) | 27.37M CAD |
Revenue Per Share (ttm) | 2.24 CAD |
Quarterly Revenue Growth (yoy) | -7.90% |
Gross Profit (ttm) | 22.86M CAD |
EBITDA | 6.51M CAD |
Net Income Avi to Common (ttm) | 5.05M CAD |
Diluted EPS (ttm) | 0.41 |
Quarterly Earnings Growth (yoy) | -26.00000000000000000000000000000000% |
Balance Sheet
Total Cash (mrq) | 26.25M CAD |
Total Cash Per Share (mrq) | 2.17 CAD |
Total Debt (mrq) | 1.35M CAD |
Total Debt/Equity (mrq) | 4.05 CAD |
Current Ratio (mrq) | 9.017 |
Book Value Per Share (mrq) | 2.763 |
Cash Flow Statement
Operating Cash Flow (ttm) | 3.96M CAD |
Levered Free Cash Flow (ttm) | 2.59M CAD |
Profile of BioSyent Inc.
Country | Canada |
State | ON |
City | Mississauga |
Address | 2476 Argentia Road |
ZIP | L5N 6M1 |
Phone | 905-206-0013 |
Website | https://www.biosyent.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water or mixing oral iron supplement; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency, as well as Feramax Pd Maintenance 45, a chewable, orange-flavored iron supplement. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
Q&A For BioSyent Inc. Stock
What is a current RX.V stock price?
BioSyent Inc. RX.V stock price today per share is 8.65 CAD.
How to purchase BioSyent Inc. stock?
You can buy RX.V shares on the TSXV exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioSyent Inc.?
The stock symbol or ticker of BioSyent Inc. is RX.V.
Which industry does the BioSyent Inc. company belong to?
The BioSyent Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does BioSyent Inc. have in circulation?
The max supply of BioSyent Inc. shares is 11.62M.
What is BioSyent Inc. Price to Earnings Ratio (PE Ratio)?
BioSyent Inc. PE Ratio is 16.32075500 now.
What was BioSyent Inc. earnings per share over the trailing 12 months (TTM)?
BioSyent Inc. EPS is 0.53 CAD over the trailing 12 months.
Which sector does the BioSyent Inc. company belong to?
The BioSyent Inc. sector is Healthcare.